Market News AIOpen the app

Lexeo Therapeutics showed an 80% drop in heart rhythm issues in its study on genetic heart disease.

TrialRead the original at Benzinga
Good for LXEO

Lexeo's interim study showed fewer heart rhythm problems among high-dose patients, favoring the company. One patient had a serious heart rhythm event, and doctors managed liver test rises.

LXEO · Lexeo Therapeutics Inc.

AI read · Good for LXEO

The AI's read

These findings give Lexeo early evidence that LX2020 may reduce heart rhythm problems. Six of 7 high-dose patients improved, and the FDA is open to a heart rhythm measure for a possible faster approval path. The results came from a small group, and the planned larger study is not expected to start until late 2027. One patient had a serious heart rhythm event, and some patients had liver test rises that doctors managed.

Get alerts for LXEO

Follow Lexeo Therapeutics Inc. (LXEO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for LXEO
Free on the App Store and Google Play, or on the web.